Coffee consumption and overall and cause-specific mortality: the Norwegian Women and Cancer Study (NOWAC) by Lukic, Marko et al.
Vol.:(0123456789) 
European Journal of Epidemiology (2020) 35:913–924 
https://doi.org/10.1007/s10654-020-00664-x
MORTALITY
Coffee consumption and overall and cause‑specific mortality: 
the Norwegian Women and Cancer Study (NOWAC)
Marko Lukic1,2  · Runa Borgund Barnung1 · Guri Skeie1 · Karina Standahl Olsen1 · Tonje Braaten1
Received: 11 March 2020 / Accepted: 15 July 2020 / Published online: 23 July 2020 
© The Author(s) 2020
Abstract
Coffee consumption has previously been reported to reduce overall and cause-specific mortality. We aimed to further investi-
gate this association by coffee brewing methods and in a population with heavy coffee consumers. The information on total, 
filtered, instant, and boiled coffee consumption from self-administered questionnaires was available from 117,228 women in 
the Norwegian Women and Cancer (NOWAC) Study. We used flexible parametric survival models to calculate hazard ratios 
(HR) and 95% confidence intervals (CI) for all-cause, cardiovascular, and cancer mortality by total coffee consumption and 
brewing methods, and adjusted for smoking status, number of pack-years, age at smoking initiation, alcohol consumption, 
body mass index, physical activity, and duration of education. During 3.2 million person-years of follow-up, a total of 16,106 
deaths occurred. Compared to light coffee consumers (≤ 1 cup/day), we found a statistically significant inverse association 
with high-moderate total coffee consumption (more than 4 and up to 6 cups/day, HR 0.89; 95% CI 0.83–0.94) and all-cause 
mortality. The adverse association between heavy filtered coffee consumption (> 6 cups/day) and all-cause mortality observed 
in the entire sample (HR 1.09; 95% CI 1.01–1.17) was not found in never smokers (HR 0.85; 95% CI 0.70–1.05). During the 
follow-up, both high-moderate total and filtered coffee consumption were inversely associated with the risk of cardiovascular 
mortality (HR 0.79; 95% CI 0.67–0.94; HR 0.80; 95% CI 0.67–0.94, respectively). The association was stronger in the analy-
ses of never smokers (> 6 cups of filtered coffee/day HR 0.20; 95% CI 0.08–0.56). The consumption of more than 6 cups/day 
of filtered, instant, and coffee overall was found to increase the risk of cancer deaths during the follow-up. However, these 
associations were not statistically significant in the subgroup analyses of never smokers. The data from the NOWAC study 
indicate that the consumption of filtered coffee reduces the risk of cardiovascular deaths. The observed adverse association 
between coffee consumption and cancer mortality is most likely due to residual confounding by smoking.
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Introduction
Average consumption of coffee in Norway reached almost 
10 kg per capita during the previous decade [1]. Filtered 
coffee continues to be the most popular brewing method, 
followed by boiled and instant coffee as the alternative brew-
ing methods [2]. According to a survey from 2017, 70% of 
Norwegians are drinking coffee daily [3].
Coffee may influence risk of disease through molecular 
and physiological mechanisms. Coffee and its constituents 
can increase carcinogen detoxification [4], affect DNA 
methylation [5], increase insulin sensitivity [6], positively 
impact liver health [7], and in addition, immunological 
mechanisms have been reported [5, 8]. Still, overall effects 
on lipid metabolism remains to be established [9]. Finally, 
caffeine, chlorogenic acid, kahweol, cafestol, and coffee 
maillard reaction products are all found to have anti-oxidant 
properties [10–14]. Via these numerous mechanisms, coffee 
and its constituents may influence human health, and thereby 
potentially affect the risk of mortality.
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Concentration and bioavailability of the constituents 
found in coffee depend on brewing methods. Coffee diter-
pens (kahweol and cafestol), as well as caffeine are found 
in higher concentrations in boiled compared to filtered cof-
fee [15, 16], similarly, the anti-oxidant activity of chlo-
rogenic acid is found to be higher in boiled compared to 
other coffee brews [15].
In a recent umbrella review on coffee, caffeine and 
health outcomes [14], coffee was found to be associated 
with a probable decreased risk of some cancer types (liver, 
endometrial), CVD and CVD mortality, Parkinson’s dis-
ease, and type 2 diabetes. Caffeine was found to probably 
decrease the risk of Parkinson’s and type 2 diabetes, but 
increased the risk of pregnancy loss.
To this day, there are several meta-analyses conducted 
in order to quantify the risk of overall and cause specific 
mortality in regards to coffee consumption [17–20]. The 
results from the meta-analyses all indicated that coffee 
consumption was associated with a lower risk of all-cause 
mortality, and in two meta-analyses, coffee consumption 
reduced the risk of mortality from cardiovascular dis-
eases (CVD). The association of coffee consumption with 
reduced cancer mortality was not as clear as for all-cause 
and CVD mortality [17]. However, data is lacking on the 
potential effects of different coffee brewing types on these 
outcomes.
In 2017, ischemic heart diseases were the leading causes 
of deaths in Norway, followed by Alzheimer’s disease, 
stroke, chronic obstructive pulmonary disease, and lung 
cancer [21]. In the present study, we aimed to investigate the 
association between high coffee consumption by different 
brewing methods and all-cause, CVD, and cancer mortality.
Materials and methods
Study sample
The Norwegian Women and Cancer (NOWAC) study is a 
nationally representative, population based cohort study that 
includes approximately 172,000 women. The NOWAC study 
has been described in detail elsewhere [22]. In short, the 
study was initiated in 1991, and random samples of Norwe-
gian women aged 30–70 years was drawn from the Norwe-
gian Central Population Registry and were invited to par-
ticipate. Our initial study cohort consisted of those women 
who completed a version of the NOWAC food frequency 
questionnaire (FFQ) that included questions on coffee con-
sumption by brewing method (filtered, instant, boiled). We 
excluded women without information on all three brewing 
methods (N = 55,220). Following these exclusions, our final 
study sample consisted of 117,228 women.
The NOWAC Study was approved by the Regional Com-
mittee for Medical Research Ethics and the Norwegian Data 
Inspectorate. All women gave written informed consent.
Assessment of coffee consumption
Women enrolled in the NOWAC study answered the fol-
lowing question on coffee consumption: “How many cups 
of each kind of coffee (boiled, filtered, instant) did you usu-
ally drink during the past year?” For each brewing method, 
women could choose between the following answers depend-
ing on the version of the FFQ: never/seldom, 1–6 cups/week, 
1 cup/day, 2–3 cups/day, 4–5 cups/day, 6–7 cups/day, and ≥ 8 
cups/day, or never/seldom, 1–3 cups/month, 1 cup/week, 2–4 
cups/week, 5–6 cups/week, 1 cup/day, 2–3 cups/day, 4–5 
cups/day, and 6–10 cups/day. We assigned a midpoint value 
for each of the categories, which were then summed up in 
order to calculate consumption of filtered, boiled, and instant 
coffee. Total coffee consumption was calculated as the com-
bined consumption of all brewing methods. For total coffee 
consumption, and within each brewing type, women were 
categorized as light consumers (≤ 1 cup/day), low-moder-
ate consumers (> 1–4 cups/day), high moderate consumers 
(> 4–6 cups/day), and heavy consumers (> 6 cups/day).
End points
We used the unique 11-digit personal number assigned to 
every legal resident in Norway to obtain information on 
death and emigration through linkage to the Norwegian Cen-
tral Population Register. We acquired information on causes 
of death in our cohort from the National Registry for Causes 
of Death. We used the 10th Revision of the International 
Statistical Classification of Diseases, Injuries and Causes 
of Death (ICD-10) to classify causes into CVD deaths that 
included stroke, coronary heart disease, and other vascular 
causes (ICD-10: I00-I99), and cancer deaths (ICD-10: C00-
D48). All-cause mortality was defined as the combination of 
CVD, cancer, and deaths from all other causes.
Statistical analysis
For the all-cause mortality, person-years were calculated 
from the beginning of the study follow-up until the date of 
emigration, death or end of the study period (December 31st 
2018), whichever occurred first. For cancer and cardiovas-
cular mortality the end of the study period was set to 31. 
December 2016, as we had information on causes of death 
only until the end of 2016.
We used flexible parametric models (by using stpm2 mod-
ule [23] in STATA version 15.0, StataCorp, Lakeway Drive, 
College Station, TX) to obtain hazard ratios (HR) with 95% 
confidence intervals (CI) for the association between coffee 
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consumption and the risk of CVD, cancer, and all-cause 
mortality. Light coffee consumers were used as the refer-
ence group, as it was not possible to differentiate between 
coffee abstainers and occasional coffee drinkers because of 
the answers offered in the FFQ. Attained age was used as 
the underlying time scale.
The final models for each outcome were adjusted 
for the following a priori selected covariates: smok-
ing status (current, former, never), age at smoking ini-
tiation (< 20, ≥ 20  years), number of pack-years (≤ 14, 
15–19, ≥ 20), body mass index (BMI ≤ 18.49, 18.5–24.9, 
25–29.9, and ≥ 30 kg/m2), alcohol consumption (0, 0.1–3.99, 
4–9.99, ≥ 10 g/day), duration of education (≤ 9, 10–12, 
13–16, ≥ 17 years), and level of physical activity (self-
reported on an increment scale from 1 to 10 and categorized 
into 1–4, 5–6, 7–10). In the analyses that required adjusting 
for smoking exposure, we modelled these by combining the 
information on smoking status, age at smoking initiation, 
and number of pack-years into five categorical variables. In 
addition, brewing method-specific analyses were adjusted 
for the two other brewing methods.
We modeled restricted cubic splines with four knots, with 
its locations based on Harrell’s recommended percentiles of 
the total coffee consumption to assess the shape of the rela-
tionship between overall coffee consumption and CVD, can-
cer, and all-cause mortality [24]. A Wald-type test was used 
to assess if the coefficients of the second and third spline 
were equal to zero. We calculated a per cup change in risk 
of the study outcomes by using a generalized least squares 
for trend estimation of summarized dose–response data [25].
In order to counteract potential residual confounding 
due to smoking, we conducted subgroup analyses on never 
smokers for all of the outcomes. Furthermore, we did the 
analyses in which we had excluded deaths that occurred dur-
ing the first year of follow-up. We also checked for potential 
effect modification of BMI, by including an interaction term 
between BMI and total coffee intake.
Results
During 3.2 million person-years of follow-up, a total of 
16,106 deaths occurred. The median follow-up time was 
20.5 years. Most of the study participants reported drink-
ing not more than 4 cups of coffee per day, with filtered 
coffee being the most frequently consumed (Table 1). The 
distribution of deaths according to levels of coffee con-
sumption is presented in supplementary Table 1.
Compared to heavy coffee consumers, light coffee 
consumers were younger at the baseline, had more years 
of attained education, and were more likely to be never 
smokers. Compared to other levels of coffee consumption, 
women that drank more than 6 cups of coffee per day were 
more likely to be current smokers (58%) and were also the 
heaviest smokers (Table 2).
Compared to light coffee consumers, high-moderate 
coffee consumers (> 4–6 cups/day) had a lower risk of 
deaths from all causes (HR 0.89, 95% CI 0.83–0.94), and 
of CVD mortality (HR 0.79, 95% CI 0.67–0.94, Tables 3 
and 5, Fig. 1) during the follow-up. In the analyses of never 
smokers, we found a strong inverse association between 
heavy coffee drinking and CVD mortality (HR 0.32, 95% 
CI 0.17–0.60), and observed a strong dose–response rela-
tionship with one additional cup of coffee per day being 
associated with a 9% lower risk of CVD deaths (95% CI 
4–14%, Table 6, Fig. 2). During the follow-up, a slightly 
increased risk of cancer deaths was observed in heavy cof-
fee consumers compared to the reference group (HR 1.14, 
95% CI 1.03–1.26, Table 7, Fig. 3). However, no statisti-
cally significant association with cancer deaths were found 
in never smokers (HR 1.09, 95% CI 0.88–1.36, Table 8, 
Fig. 3).    
Finally, there was a significant departure from lin-
earity as shown by the Wald-type test in the association 
between total coffee consumption and the total, CVD, and 
Table 1  Distribution of 
participants according to total, 
filtered, instant, and boiled 
coffee consumption, the 











25,115 (21.4) 36,400 (31.1) 33,883 (28.9) 21,830 (18.6)
Filtered coffee consumption
≤ 1 cup/day > 1–4 cups/day > 4–6 cups/day > 6 cups/day
51,611 (44.0) 28,431 (24.3) 24,194 (20.6) 12,992 (11.1)
Instant coffee consumption
≤ 1 cup/day > 1–4 cups/day > 4–6 cups/day > 6 cups/day
108,162 (92.3) 5923 (5.1) 2214 (1.9) 929 (0.8)
Boiled coffee consumption
≤ 1 cup/day > 1–4 cups/day > 4–6 cups/day > 6 cups/day
95,254 (81.3) 8726 (7.4) 7823 (6.7) 5425 (4.6)
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cancer mortality in the whole sample (p < 0.001, p = 0.03, 
p = 0.005, respectively). However, no significant departure 
was found in never smokers (p = 0.62, p = 0.17, p = 0.79, 
respectively).
For filtered coffee, consuming more than 6 cups per day 
was associated with a slightly increased risk of all-cause 
mortality in the whole sample (HR 1.09, 95% CI 1.01–1.17), 
but not in never smokers (HR 0.85, 95% CI 0.70–1.05, 
Table 2  Characteristics of the study sample by total coffee consumption, the Norwegian Women and Cancer Study, 1996–2016
SD standard deviation













Participants at baseline, N (%) 25 115 (21.4) 36 400 (31.1) 33 883 (28.9) 21 830 (18.6)
Age at baseline (y), mean (SD) 45.7 (9) 49.2 (8.7) 47.7 (8.4) 46.7 (8.0)
Smoking status at baseline, %
Never 45.9 42.5 30.5 15.9
Former 30.4 35.9 32.9 26.1
Current 23.7 21.6 36.6 58.0
Age at smoking initiation (y), mean (SD) 19.1 (4.8) 19.6 (5.5) 19.7 (5.4) 19.6 (5.6)
Number of pack-years smoked at baseline, mean (SD) 7.6 (7.6) 7.7 (8.1) 9.2 (8.0) 12.4 (8.8)
Duration of education (y), mean (SD) 13.1 (3.6) 12.5 (3.5) 11.7 (3.3) 10.9 (3.1)
Body mass index, mean (SD) 23.9 (4.1) 24.0 (3.8) 24.0 (3.7) 24.1 (3.9)
Physical activity level, mean (SD) 5.5 (1.9) 5.7 (1.8) 5.6 (1.9) 5.5 (2.1)
Alcohol consumption (g/day), mean (SD) 3.1 (6.2) 3.4 (4.9) 3.2 (4.6) 3.2 (7.0)
Table 3  Hazard ratios (HRs) with 95% confidence intervals (CI) of all-cause mortality according to total, filtered, instant, and boiled coffee con-
sumption in the Norwegian Women and Cancer Study
Cat. categorical
a Adjusted for smoking status, age at smoking initiation, number of pack-years smoked, body mass index (cat.), alcohol consumption (g/day) 
(cat.), physical activity (cat.), years of attained education (cat.)
b Adjusted for smoking status, age at smoking initiation, number of pack-years smoked, body mass index (cat.), alcohol consumption (g/day) 





Total coffee consumption Filtered coffee consumption Instant coffee consumption Boiled coffee consumption
Age-adjusted 
N = 117 228
n = 12 364
Multivariablea 




n = 12 364
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ableb 




n = 12 364
Multivari-
ableb 




n = 12 364
Multivariableb 









































































1.00 (0.99–1.01) 1.00 (0.99–1.01) 1.00 (0.98–1.01) 0.99 (0.98–0.99)
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Tables 3 and 4). A low-moderate and high-moderate con-
sumption of filtered coffee was associated with the reduced 
risk of CVD mortality (Table 5). In the analyses of never-
smokers, we found an even stronger association, with a 
strong inverse association between heavy filtered coffee 
consumption and CVD deaths (HR 0.20; 95% CI 0.08–0.56, 
Table 6). At the same time, one additional cup of filtered 
coffee per day was associated with a 10% lower risk of CVD 
deaths (95% CI 5–16%, Fig. 2). We found a 23% increased 
risk of cancer mortality among heavy filtered coffee consum-
ers (95% CI 11–36%, Table 7), but no significant associa-
tions between filtered coffee consumption and cancer deaths 
were found in never-smokers (Table 8).
We did not observe an association between instant coffee 
consumption and all-cause and CVD mortality during the 
follow-up (Tables 3 and 5). Heavy instant coffee consump-
tion was associated with a risk of cancer deaths in the whole 
sample (HR 1.40, 95% CI 1.09–1.81, Table 7), but not in 
never-smokers (HR 0.91, 95% CI 0.38–2.21, Table 8).
No association was found between boiled coffee con-
sumption and any of the outcomes. We did, however 
observed a borderline non-significant lower risk of CVD 
deaths among never smokers who drank more than 6 cups 
of boiled coffee per day compared to the reference group 
(HR 0.32, 95% CI 0.10–1.02, Table 6). The results from the 
analyses with and without smoking adjustment are presented 
in the supplementary Tables 2–4.
The risk estimates from the lag analyses were similar to 
those from the analyses that included the entire study sample 
(results not shown). We did not find evidence that BMI was 
an effect modifier in the association between total coffee 
consumption and any of the studied outcomes (results not 
shown).
Discussion
The present study used data from the NOWAC study, a large 
prospective population based cohort of females, to inves-
tigate a possible association between coffee consumption, 
different coffee brewing methods, and all-cause, CVD, and 
cancer mortality. We found that, at large, total and filtered 
coffee consumption was associated with reduced all-cause 
and CVD mortality. However, in the full cohort, the highest 
coffee consumption (more than 6 cups/day) was associated 
with increased mortality, but this phenomenon is likely due 
to residual confounding by smoking, as the association is 
not present in the non-smokers. Similarly, the association 
between coffee and increased cancer mortality in the full 
cohort is not present in the non-smoking sub-group analysis.
Fig. 1  Spline regression models for total coffee intake in relation to all-cause mortality in a whole sample (a) and in never-smokers (b). (Solid 
lines—HR, dashed lines—95% CE)
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A recent umbrella review concluded that coffee may be 
viewed as part of a healthy diet [14]. This is in line with 
our results on reduced all-cause and CVD mortality, par-
ticularly in non-smokers. In some subgroups of our results 
(according to outcome, brewing type, smoking status), we 
find tendency towards lower mortality by dose of coffee, as 
seen in the non-smokers for CVD mortality. As summarized 
in the umbrella review, beneficial effects of coffee was found 
for a number of cancer outcomes, metabolism-related out-
comes including CVD, as well as neurological conditions. 
More specifically, for all-cause mortality, beneficial effects 
of coffee has been identified in both European [26–28] and 
American [29–31] cohorts, as well as in three meta-analyses 
[17, 32, 33]. The same overall picture is true for three meta-
analyses [17, 32, 33], and several single cohorts studying 
CVD mortality [26, 28, 29]. The potential dose–response 
relationship between coffee and CVD mortality in our results 
is also recognizable from the majority of the available data: 
Grosso discusses that there may be a linear dose/response 
relationship, alternatively that 4–5 cups/day is the most ben-
eficial dose [14].
We found an increased risk of cancer mortality when con-
suming more than 6 cups of coffee per day (total, filtered, 
and instant), but this was not significant when looking at the 
non-smokers. This suggest that residual confounding from 
smoking still influences the multivariate analysis of the 
whole cohort. Several meta-analyses have previously con-
sidered the association between coffee and cancer mortality. 
Kim et al. found a non-linear inverse association between 
coffee consumption and cancer mortality [33]. However, 
the association between coffee and cancer mortality was 
not apparent at higher coffee consumptions, and the authors 
suggest that this might be due to residual confounding from 
smoking. Similarly, a meta-analysis by Grosso et al. only 
found a risk reduction for cancer mortality when looking at 
never smokers [32]. However, no association was found in a 
third meta-analysis [17]. The residual smoking confounding 
is also likely seen in the pooled analysis of Ding et al., who 
identified an increased risk for lung cancer deaths by coffee 
consumption, but not in sub-group analysis of never smokers 
[31]. Indeed, when looking at the never smokers, they found 
an inverse association between coffee consumption (3.1–5 
cups/day) and cancer mortality.
Mechanisms
Several hypotheses have been put forward to explain the 
association between coffee and health, related to the bioac-
tive compounds found in coffee. However, the concentra-
tion of these compounds vary according to coffee species, 
Fig. 2  Spline regression models for total coffee intake in relation to cardiovascular mortality in a whole sample (a) and in never-smokers (b). 
(Solid lines—HR, dashed lines—95% CE)
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Fig. 3  Spline regression models for total coffee intake in relation to cancer mortality in a whole sample (a) and in never-smokers (b). (Solid 
lines—HR, dashed lines—95% CE)
Table 4  Hazard ratios (HRs) with 95% confidence intervals (CI) of all-cause mortality according to total, filtered, instant, and boiled coffee con-
sumption in the Norwegian Women and Cancer Study-never smokers
Cat. categorical
a Adjusted for body mass index (cat.), alcohol consumption (g/day) (cat.), physical activity (cat.), years of attained education (cat.)
b Adjusted for body mass index (cat.), alcohol consumption (g/day) (cat.), physical activity (cat.), years of attained education (cat.), and mutually 






































































































0.98 (0.97–1.00) 0.98 (0.96–0.99) 1.02 (0.98–1.06) 0.99 (0.96–1.01)
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Table 5  Hazard ratios (HRs) with 95% confidence intervals (CI) of cardiovascular mortality according to total, filtered, instant, and boiled coffee 
consumption in the Norwegian Women and Cancer Study
Cat. categorical
a Adjusted for smoking status, age at smoking initiation, number of pack-years smoked, body mass index (cat.), alcohol consumption (g/day) 
(cat.), physical activity (cat.), years of attained education (cat.)
b Adjusted for smoking status, age at smoking initiation, number of pack-years smoked, body mass index (cat.), alcohol consumption (g/day) 










N = 98 553
n = 1328
Age-adjusted 




N = 98 553
n = 1328
Age-adjusted 



















































































0.98 (0.96–1.00) 0.98 (0.96–1.00) 0.97 (0.93–1.02) 0.98 (0.95–1.01)
Table 6  Hazard ratios (HRs) with 95% confidence intervals (CI) of cardiovascular mortality according to total, filtered, instant, and boiled coffee 
consumption in the Norwegian Women and Cancer Study—never smokers
Cat. categorical
a Adjusted for body mass index (cat.), alcohol consumption (g/day) (cat.), physical activity (cat.), years of attained education (cat.)
b Adjusted for body mass index (cat.), alcohol consumption (g/day) (cat.), physical activity (cat.), years of attained education (cat.), and mutually 






































































































0.91 (0.86–0.96) 0.90 (0.84–0.95) 0.95 (0.86–1.05) 0.95 (0.88–1.02)
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Table 7  Hazard ratios (HRs) with 95% confidence intervals (CI) of cancer mortality according to total, filtered, instant, and boiled coffee con-
sumption in the Norwegian Women and Cancer Study
Cat.: categorical
a Adjusted for smoking status, age at smoking initiation, number of pack-years smoked, body mass index (cat.), alcohol consumption (g/day) 
(cat.), physical activity (cat.), years of attained education (cat.)
b Adjusted for smoking status, age at smoking initiation, number of pack-years smoked, body mass index (cat.), alcohol consumption (g/day) 










N = 98 553
n = 4344
Age-adjusted 




N = 98 553
n = 4344
Age-adjusted 




N = 98 553
n = 4344
Age-adjusted 
N =  117 228
n = 5483
Multivariableb 









































































1.02 (1.01–1.03) 1.02 (1.01–1.03) 1.01 (0.99–1.04) 1.00 (0.99–1.02)
Table 8  Hazard ratios (HRs) with 95% confidence intervals (CI) of cancer mortality according to total, filtered, instant, and boiled coffee con-
sumption in the Norwegian Women and Cancer Study—never smokers
Cat. categorical
a Adjusted for body mass index (cat.), alcohol consumption (g/day) (cat.), physical activity (cat.), years of attained education (cat.)
b Adjusted for body mass index (cat.), alcohol consumption (g/day) (cat.), physical activity (cat.), years of attained education (cat.), and mutually 






































































































1.01 (0.98–1.03) 1.01 (0.99–1.04) 0.98 (0.93–1.05) 0.99 (0.96–1.03)
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genetics, roasting and brewing types [34]. In addition, het-
erogeneity in issues related to study design (doses, dura-
tion, choice of biomarker, measurement methods) adds to 
the variability of reported findings on bioactive constituents 
[35]. In line with this, we do see some differences in the 
results according to brewing type, with boiled coffee being 
the least favorable.
Compounds like diterpenes, trigonelline, melanoidins, 
caffeine, and chlorogenic acid all have known anti-oxidant 
properties that might influence risk of mortality when con-
sumed regularly [10–14]. Our results on boiled coffee may 
be related to the cholesterol rising effect of the diterpenes 
cafestol and kahweol [36]. In filtered coffee, these sub-
stances are left in the filter paper, sparing filtered coffee-
drinkers of their potential harmful CVD-related effects. In 
our study, the association of total and filtered coffee with 
reduced all-cause and CVD mortality, is at large not evident 
in the boiled coffee group. Still, increased all-cause, CVD, 
and cancer mortality in the boiled coffee group is only found 
in the full cohort and not in the non-smokers, again pointing 
to the impact of smoking. Unlike their serum lipid raising 
effect, the coffee diterpenes may have favorable impact on 
cancer risk, due to their beneficial effect on oxidative stress 
and inflammatory processes [35]. [36]. As summarized by 
Ren et al., the coffee diterpenes may have an inhibitory effect 
at multiple stages of cancer development, including tumo-
rigenesis, tumor cell proliferation, and metastasis [36]. The 
mechanisms involve inhibition of detoxifying CYP enzymes, 
induction of apoptosis, and inhibition of angiogenesis [36]. 
However, no such beneficial effect is evident in our data, not 
even in the never smokers.
Trigonelline was reported to have hypoglycemic, neuro-
protective, anti-carcinogenic and antibacterial effects [34]. 
Coffee melanoidins are best known for their potential pro-
biotic effect, but they also have a possible anti-carcinogenic 
effect [34]. Caffeine has a known central nervous system 
stimulatory effect, as well as an impact on cardiovascular 
health due to possible acute increase in heart rate and blood 
pressure [34]. Habitual coffee drinkers will experience less 
of this blood pressure rising effect due to increased toler-
ance of caffeine [37]. A recent meta-analysis that looked at 
both caffeinated and decaffeinated coffee consumption and 
all-cause mortality found no difference in the risk reduction 
(per 1 cup/day increments) from all-cause mortality between 
caffeinated and decaffeinated coffee [20]. This indicates that 
the effect of coffee on all-cause mortality might be unrelated 
to the caffeine consumption. Finally, chlorogenic acid, one 
of the major phenols present in coffee, may influence oxida-
tive processes, although this may vary according to the roast 
of the coffee consumed [35].
Taken together, several substances from coffee can have 
a biological impact, and may influence all-cause, CVD, 
and cancer mortality. However, the potential bioactive 
concentration of substances, the underlying biological 
mechanisms, and potential synergistic effects from these 
substances in coffee are still not completely understood.
Strengths and limitations
The main strengths of the present study are its prospective 
design and the relatively large sample size, with sufficient 
number of cases to detect differences between the coffee 
consumption groups in each of the outcomes. The response 
rate in the NOWAC study (52.7%) is similar to other popula-
tion-based cohorts. A validation study showed that the study 
responders did not differ from the source population and 
negligible differences were found only in level of education 
[38]. Linkage to the Norwegian Central Population Regis-
ter and the National Registry for Causes of Death via the 
unique person number allowed us to obtain virtually com-
plete follow-up. Finally, a 24-h dietary recall study aiming to 
validate the FFQs used in the NOWAC cohort showed a high 
validity of information on coffee consumption (Spearman’s 
correlation coefficient r = 0.82) [39].
There are numerous limitations in our study. We did not 
have information on consumption of espresso, cappuccino, 
caffè latte, macchiato, or decaffeinated coffee for the entire 
studied cohort. However, the consumption of these types of 
coffee was relatively rare among Norwegian women at the 
time the baseline information were collected [40, 41]. In 
addition, information on condiments added in coffee, such 
as sugar, sweeteners, creamer, and milk were also available 
from a limited number of women in the cohort.
As coffee consumption was self-reported, misclassifica-
tion cannot be ruled out, despite the results from the valida-
tion study. This potential misclassification was most likely 
non-differential among the comparison groups, hence, our 
observed associations may be underestimated.
We lacked sufficient details on smoking exposure (e.g. 
lifetime exposure to secondhand smoke) which would have 
allowed us to optimally adjust for smoking. As heavy cof-
fee consumption is strongly associated with heavy smok-
ing, residual confounding was highly probable in our study. 
Hence, the results from the analyses of the entire studied 
sample should be interpreted with caution. In order to 
remove the confounding effect of smoking, we repeated all 
the analyses in never smoker subgroup. However, the analy-
ses of instant and boiled coffee consumption in never smok-
ers were to a certain extent statistically underpowered, as the 
number of cases within the heavy consumption categories 
of these brewing types might have been too low to detect 
significant risk differences.
Finally, some residual confounding effect of the other 
adjustment covariates is probable, due to measurement error 
in self-reported life-style variables.
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Conclusion
Our data show that coffee consumption, in particular of the 
filtered brewing type, reduces the risk of cardiovascular 
deaths. The observed stronger association in never smok-
ers indicates that a residual confounding by smoking is 
present, which likely explains the observed adverse asso-
ciation between coffee consumption and cancer mortality.
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